Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma

► Vasoactive intestinal peptide (VIP) increases adhesion of renal carcinoma cells. ► VIP decreases migration and extracellular-matrix degradation in tumor renal cells. ► VIP lowers tumor VEGF expression and nuclear levels of β-catenin and NFκB p50 unit. ► VIP acts through VPAC1/2 receptors (they were blocked with JV-1-53 antagonist). ► VIP and its agonists have a potential therapeutical role in clear renal cell cancer.